Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 4NIH 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 3

Interventions

aldesleukin 65Cyclophosphamide 45fludarabine phosphate 30fludarabine 27Interleukin-2 24incomplete Freund's adjuvant 22Ipilimumab 17Specimen Handling 14MART-1 Antigen 14CTLA-4 Antigen 14sargramostim 13Magnetic Resonance Spectroscopy 13Biopsy 13montanide ISA 51 11Nivolumab 11Filgrastim 11Sorafenib 10Interferon-alpha 9trametinib 8pembrolizumab 8dabrafenib 8Sirolimus 7Bevacizumab 7temsirolimus 6Temozolomide 6Taxes 5Paclitaxel 5Introns 5Gene Expression Profiling 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Melanoma × gp100 Melanoma Antigen × Clear all
NCT00019682 2017-11-20

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

National Cancer Institute (NCI)

Phase 3 Completed
185 enrolled 11 charts
Dermatologic

Melanoma

NCT00303836 2013-06-06

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Terminated
58 enrolled
Dermatologic

Melanoma

NCT00006243 2013-01-25

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

National Cancer Institute (NCI)

Phase NA Completed
30 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡